文献类型：期刊文献

英文题名：GSH/pH dual-responsive supramolecular hybrid vesicles for synergistic enzymatic/chemo-tumor therapy

作者：He, Jianping[1];Chen, Jianzhuang[1];Niu, Dechao[1];Jia, Xiaobo[1];Wang, Qinghua[1];Hao, Jina[1];Gu, Jinlou[1];Li, Yongsheng[1];Shi, Jianlin[1,2]

机构：[1]East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Lab Low Dimens Mat Chem,Key Lab Ultrafine Mat,Min, Shanghai 200237, Peoples R China;[2]Chinese Acad Sci, Shanghai Inst Ceram, State Lab High Performance Ceram & Superfine Micr, Shanghai 200050, Peoples R China

年份：2020

卷号：18

外文期刊名：APPLIED MATERIALS TODAY

收录：;EI(收录号：20193907481812);WOS:【SCI-EXPANDED(收录号:WOS:000530651300006)】；

基金：This work was financially supported by the National KeyResearch and Development Program of China (Grant Nos. 2018YFC1105702 and 2016YFA0203700); The National Natural Science Foundation of China for Innovative Research Groups (No. 51621002); NSFC (Grant Nos. 51572083, 51972112); Program ofShanghai Academic/Technology Research Leader (18XD1401400); Basic Research Program of Shanghai (17JC1404702); Leading talents in Shanghai in 2018; The Program for Professor of SpecialAppointment (Eastern Scholar) at Shanghai Institutions of HigherLearning; The 111 project (B14018) and the Fundamental ResearchFunds for Central Universities (222201718002).

语种：英文

外文关键词：Dual-responsiveness; Supramolecular hybrid vesicle; Enzymatic/chemo-Synergistic therapy

摘要：Supramolecular amphiphilic vesicles are promising carriers in tumor therapy due to their excellent loading capabilities for both hydrophilic and hydrophobic cargos, especially for biomacromolecules such as proteins, enzymes and plasmids. However, the poor circulating stability and unsatisfied therapeutic efficiency greatly limit their in vivo applications. To address these issues, herein, we design and develop a new kind of GSH/pH dual-responsive supramolecular hybrid vesicles (SHVs) to encapsulate and deliver simultaneously biomacromolecule glucose oxidase (GOD) and chemotherapeutic drug docetaxel (DTX) for synergistic enzymatic/chemo-tumor therapy. The SHVs are constructed by the self-assembly of beta-CD-poly(epsilon-caprolactone), ferrocene-poly (acrylic acid) and pillar [5] arenes via the terminal beta-CD/Fc host-guest interaction, followed by cross-linking with 3-mercaptopropyltrimethoxysilane and poly (ethylene glycol) modification. As a vehicle for both hydrophilic and hydrophobic cargos, the resulting GOD/DTX co-loaded SHVs exhibit excellent synergistic enzymatic/chemo-tumor therapeutic ability with a combination index (CI = 0.285) of GOD and DTX in cellular level and high tumor inhibitory rate of 95.3% in vivo. Consequently, the resulting hybrid vesicles can be used as efficient and safe carriers for biomacromolecules in further cancer therapy. (C) 2019 Elsevier Ltd. All rights reserved.